Table 1.
Serum concentration, specificity and sensitivity of endocan in diseases.
| Disease | Serum concentration | Control | Concentration (critical value) | Specificity (%) | Sensitivity (%) | PMID |
|---|---|---|---|---|---|---|
| HT | 1.18 ng/mL 1.31 ng/mL | 0.73 ng/mL 0.74 ng/mL |
25588082 24402320 |
|||
| Essential HT | 34.2 ng/mL | 24.1 ng/mL | 30630336 | |||
| Primary HT | 2.03 ng/mL | 1.09 ng/mL | 29084442 | |||
| HTwith CVD | 1.47 ng/mL | 0.73ng/mL | 25588082 | |||
| HT without CAD HT with CAD |
1.31 ng/Ml 1.63 ng/mL | 0.76 ng/mL | 26200037 | |||
| Obstructive CAD | 382.7 pg/mL | 268.0 pg/mL | 26744512 | |||
| Microvascular angina | 324.3 pg/mL | 268.0 pg/mL | 26744512 | |||
| Cirrhosis | 2.6 (0.7–3.6) ng/mL | 31539885 | ||||
| Cirrhosis and DM | 4.08 ng/mL | 31539885 | ||||
| Compensated cirrhosis |
1.98 ng/mL | 0.95 ng/mL | 28614777 | |||
| Decompensated cirrhotic | 3.2 ng/ml (No infection) 6.2 ng/ml (infection) | 0.95 ng/mL | ≥2.05 ng/ml | 85 | 76.1 | 28614777 |
| T2D | 491.8 pg/mL | 228.7 pg/L | 32767341 | |||
| NAFLD | 1.23 ng/mL | 0.68 ng/mL | 28922438 | |||
| NAFLD | 146.56 pg/mL | 433.71 pg/mL | 122.583 pg/mL | 90 | 71.79 | 32317862 |
| STEMI | 1.6 ng/mL | 2.7 ng/mL | 1.7 ng/mL | 73.6 | 76.1 | 27178721 |
| SCF | 2.07 ng/mL | 3.71 ng/mL | 2.3 ng/mL | 75.2 | 77.2 | 26607436 |
| ISR | 2.56 ng/mL | 1.43 ng/mL | 1.625 ng/mL | 78 | 86 | 32201461 |
HT, Hypertension; CVD, Cardiovascular diseases; CAD, Coronary atherosclerotic heart disease; DM, diabetes; T2D, Type 2 diabetes; NAFLD, non-alcoholic fatty liver disease; STEMI, ST-segment elevation myocardial infarction; SCF, slow coronary flow; ISR, in-stent restenosis.